Cargando…
Main considerable factors for correct laboratory test interpretation under DOA treatment
SUMMARY: To avoid misinterpretation and mismanagement clinicians should be aware of the interference of new direct oral anticoagulants (DOA) on coagulation assays. A variety of oral anticoagulants targeting specific coagulation factors has already entered the market, and new indications for DOA will...
Autores principales: | Mani, Helen, Lindhoff-Last, Edelgard |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3842690/ https://www.ncbi.nlm.nih.gov/pubmed/24176012 http://dx.doi.org/10.1186/1477-9560-11-22 |
Ejemplares similares
-
New oral anticoagulants in patients with nonvalvular atrial fibrillation: a review of pharmacokinetics, safety, efficacy, quality of life, and cost effectiveness
por: Mani, Helen, et al.
Publicado: (2014) -
Thromboembolic Antiphospholipid Syndrome (APS): Efficacy and Safety of Different Anticoagulants-Results of the APSantiCO Registry
por: Schulz, Annabel, et al.
Publicado: (2022) -
The APSANTICO Study: A Prospective Observational Study to Evaluate Antiphospholipid Antibody Profiles in Patients with Thromboembolic Antiphospholipid Syndrome (APS) after COVID-19 Infection and/or Vaccination
por: Ott, Olivia, et al.
Publicado: (2023) -
No Influence of Dabigatran Anticoagulation on Hemorrhagic Transformation in an Experimental Model of Ischemic Stroke
por: Bohmann, Ferdinand, et al.
Publicado: (2012) -
CAI is DOA
por: Hamilton, Daniel S.
Publicado: (2021)